Literature DB >> 6319581

A structural investigation of the Epstein-Barr (EB) virus membrane antigen glycoprotein, gp340.

A J Morgan, A R Smith, R N Barker, M A Epstein.   

Abstract

Epstein-Barr (EB) virus membrane antigen (MA) glycoprotein (gp340) purified by a molecular weight-based technique has been subjected to biochemical analysis. Following treatment with glycosidases or tunicamycin during synthesis, the carbohydrate moiety was found to be made up of both O-linked and N-linked types and to constitute about 50% of the molecular mass. Digestion studies with neuraminidase and oligosaccharidase have indicated that the molecule is heavily sialated with most of the sialic acid located on the O-linked sugars. The high carbohydrate content of gp340 appears to confer resistance to proteolysis; thus, V8 protease was only effective at concentrations above 1 mg/ml when three large fragments of mol. wt. 330K, 190K and 160K were generated. Removal of sialic acid before V8 protease digestion did not alter this pattern nor affect the antigenicity of the digestion fragments. Antigenicity of the intact molecule was likewise unaffected by removal of sialic acid nor were the O-linked and N-linked carbohydrate moieties essential for this property. The binding of virus-neutralizing human sera and monoclonal antibody by gp340 from which either O-linked or N-linked sugars had been removed seems to indicate that the sites on the molecule that generate the neutralizing antibodies are present in the protein component. The significance of these results is discussed in relation to the development of a subunit vaccine against EB virus.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6319581     DOI: 10.1099/0022-1317-65-2-397

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

1.  Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340.

Authors:  R J Pither; C X Zhang; C Shiels; J Tarlton; S Finerty; A J Morgan
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

Review 2.  Control of viral disease: the development of Epstein-Barr virus vaccines.

Authors:  A J Morgan
Journal:  Springer Semin Immunopathol       Date:  1991

3.  Subcellular distribution and life cycle of Epstein-Barr virus in keratinocytes of oral hairy leukoplakia.

Authors:  J P Rabanus; D Greenspan; V Petersen; U Leser; H Wolf; J S Greenspan
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

4.  Localization of Epstein-Barr virus envelope glycoproteins on the inner nuclear membrane of virus-producing cells.

Authors:  M R Torrisi; M Cirone; A Pavan; C Zompetta; G Barile; L Frati; A Faggioni
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

5.  Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells.

Authors:  Y Whang; M Silberklang; A Morgan; S Munshi; A B Lenny; R W Ellis; E Kieff
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

6.  Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB.

Authors:  M Gong; T Ooka; T Matsuo; E Kieff
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

7.  The herpes simplex virus UL20 protein compensates for the differential disruption of exocytosis of virions and viral membrane glycoproteins associated with fragmentation of the Golgi apparatus.

Authors:  E Avitabile; P L Ward; C Di Lazzaro; M R Torrisi; B Roizman; G Campadelli-Fiume
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

8.  Modification of Epstein-Barr virus replication by tunicamycin.

Authors:  L M Hutt-Fletcher; N Balachandran; P A LeBlanc
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

9.  Antigens of infectious laryngotracheitis herpesvirus defined by monoclonal antibodies.

Authors:  J J York; S Sonza; M R Brandon; K J Fahey
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 10.  The 1986 Walter Hubert lecture. Recent studies on a vaccine to prevent EB virus-associated cancers.

Authors:  M A Epstein
Journal:  Br J Cancer       Date:  1986-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.